Biohaven Pharmaceutical Holding Company Ltd. BHVN Balance Sheet

Biohaven pharmaceutical holding company ltd. (BHVN)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16
Assets
Current assets:
Cash
428,239	316,727	416,574	465,739	217,407	264,249	168,185	217,452	104,206	131,468	175,754	204,290	52,286	23,565
Trade receivables, net
4,337	0	-	-	-	-	-	-	-	-	-	-	-	-
Inventories
4,582	0	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
37,288	11,554	6,596	8,613	9,966	8,090	14,795	10,150	10,467	5,197	3,749	4,326	883	470
Total current assets
474,446	328,281	423,170	474,352	227,373	272,339	182,980	227,602	114,673	136,665	179,503	208,616	53,169	24,035
Property and equipment, net
8,933	8,152	7,460	7,433	7,157	6,248	4,891	3,792	2,936	2,344	267	92	43	26
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	2,399	-
Equity method investment
3,958	5,338	7,106	9,099	10,514	11,414	7,156	7,853	8,494	7,847	4,900	5,538	4,511	2,753
Intangible assets, net
41,259	0	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
4,073	2,493	1,351	24	36	11	64	43	32	32	-	-	-	203
Restricted cash
-	-	-	-	-	-	-	-	-	-	0	0	60	-
Deferred tax assets
-	-	-	-	-	-	-	-	-	-	-	9	9	-
Total assets
532,669	344,264	439,087	490,908	245,080	290,012	195,091	239,290	126,135	146,888	184,670	214,255	60,191	27,017
Liabilities and Shareholders’ Equity
Current liabilities:
Notes payable, net of discount
-	-	-	-	-	-	-	-	-	-	-	4,785	4,489	4,216
Accounts payable
29,703	14,071	11,562	13,502	8,210	10,752	4,658	4,027	9,051	4,721	8,753	5,986	4,022	746
Accrued expenses and other current liabilities
76,770	52,102	35,644	31,167	15,483	8,782	10,606	8,728	7,814	4,708	13,360	6,750	6,931	2,980
Current portion of mandatorily redeemable preferred shares
15,625	0	-	-	-	-	-	-	-	-	-	-	-	-
Total current liabilities
122,098	66,173	47,206	44,669	23,693	19,534	15,264	12,755	16,865	9,429	22,113	17,521	15,442	7,942
Liability related to sale of future royalties
151,454	144,111	136,799	129,487	124,332	117,515	111,919	106,282	-	0	-	-	-	-
Mandatorily redeemable preferred shares, net
136,404	103,646	99,268	94,890	-	0	-	-	-	-	-	-	-	-
Derivative liability
650	37,690	36,795	35,078	-	0	-	-	-	-	0	-	223	512
Fair value of warrant liability
-	-	-	-	-	-	0	0	-	4,021	6,289	3,863	1,234	780
Contingent equity liability
-	-	-	-	-	-	-	-	-	-	-	-	22,313	18,938
Notes payable to related parties
-	-	-	-	-	-	-	-	-	-	-	-	602	595
Other long-term liabilities
105	68	43	43	44	2,043	2,095	1,423	1,454	1,467	75	19	19	13
Total liabilities
410,711	351,688	320,111	304,167	148,069	139,092	129,278	120,460	18,319	14,917	28,477	21,403	39,833	28,780
Commitments and contingencies
-	-	-	-	-	-	0	0	0	-	0	0	0	0
Series A convertible preferred shares, no par value, 0 and 11,242,172 shares authorized as of December 31, 2017 and December 31, 2016, respectively; 0 and 4,948,369 shares issued and outstanding as of December 31, 2017 and December 31, 2016, respectively; aggregate liquidation preference of $0 and $45,976 as of December 31, 2017 and December 31, 2016, respectively
-	-	-	-	-	-	-	-	-	-	-	-	73,900	43,270
Shareholders’ equity (deficit):
Common shares, no par value; 200,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 58,387,948 and 52,385,283 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively
1,175,139	881,426	874,589	844,966	556,345	554,384	418,273	413,225	367,730	311,061	310,635	310,635	20,296	19,944
Additional paid-in capital
92,129	83,523	67,496	58,717	46,538	40,104	36,358	32,982	28,194	23,556	21,122	14,866	20,371	10,479
Accumulated deficit
-1,145,310	-972,373	-823,109	-716,942	-505,872	-443,568	-388,818	-327,377	-288,108	-202,646	-175,564	-132,649	-94,209	-75,456
Total shareholders’ equity (deficit)
121,958	-7,424	118,976	186,741	97,011	150,920	65,813	118,830	107,816	131,971	156,193	192,852	-53,542	-45,033
Total liabilities and shareholders’ equity
532,669	344,264	439,087	490,908	245,080	290,012	195,091	239,290	126,135	146,888	184,670	214,255	60,191	27,017